Hiroto Inaba

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Herpes simplex virus pneumonia in a patient with ependymoma
    Hiroto Inaba
    Divisions of Pediatric Hematology Oncology, Children s Hospital of Michigan, Detroit, Michigan 38105, USA
    J Pediatr Hematol Oncol 26:108-11. 2004
  2. doi request reprint Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
    Shuiying Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale Street, DTRC Room D1034, Mail Stop 314, Memphis, TN 38105, USA
    Mol Cancer Ther 7:1110-20. 2008
  3. doi request reprint Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 113:522-9. 2008
  4. pmc Acute lymphoblastic leukaemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Lancet 381:1943-55. 2013
  5. pmc Effect of body mass index on the outcome of children with acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:5989-96. 2012
  6. pmc Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, MS 260, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:3625-32. 2012
  7. pmc Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:3293-300. 2011
  8. pmc Glucocorticoid use in acute lymphoblastic leukaemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Lancet Oncol 11:1096-106. 2010
  9. pmc Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 117:1313-20. 2011
  10. pmc Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 116:2020-30. 2010

Detail Information

Publications45

  1. ncbi request reprint Herpes simplex virus pneumonia in a patient with ependymoma
    Hiroto Inaba
    Divisions of Pediatric Hematology Oncology, Children s Hospital of Michigan, Detroit, Michigan 38105, USA
    J Pediatr Hematol Oncol 26:108-11. 2004
    ..HSV must be considered in the differential diagnosis of patients with interstitial pneumonia and T-cell deficiency, especially after craniospinal irradiation...
  2. doi request reprint Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
    Shuiying Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, 332 North Lauderdale Street, DTRC Room D1034, Mail Stop 314, Memphis, TN 38105, USA
    Mol Cancer Ther 7:1110-20. 2008
    ..Our results highlight the pharmacologic features of sorafenib that may provide it an advantage in the treatment of AML...
  3. doi request reprint Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 113:522-9. 2008
    ..To the authors' knowledge, no recently published study has evaluated the management and clinical course in this regard, especially in relation to pediatric patients...
  4. pmc Acute lymphoblastic leukaemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital and University of Tennessee Health Science Center, Memphis, TN 38105, USA
    Lancet 381:1943-55. 2013
    ....
  5. pmc Effect of body mass index on the outcome of children with acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:5989-96. 2012
    ..The effect of body mass index (BMI) on the treatment outcomes of children with acute myeloid leukemia (AML) is unclear and needs further evaluation...
  6. pmc Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, MS 260, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:3625-32. 2012
    ..Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value...
  7. pmc Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:3293-300. 2011
    ..To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia...
  8. pmc Glucocorticoid use in acute lymphoblastic leukaemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Lancet Oncol 11:1096-106. 2010
    ..The selection of the type and dose of glucocorticoid should be based on the risk of relapse, treatment phase, and the chemotherapeutic drugs used concomitantly...
  9. pmc Randomized trial of 2 dosages of prophylactic granulocyte-colony-stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 117:1313-20. 2011
    ..However, the optimal G-CSF dosage for patients with AML has not been determined. To the authors' knowledge, G-CSF dosages have not been compared in a randomized AML study...
  10. pmc Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 116:2020-30. 2010
    ..The number of long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is increasing; however, few studies have addressed their long-term pulmonary function...
  11. pmc Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 116:98-105. 2010
    ..The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed...
  12. ncbi request reprint Pulmonary alveolar proteinosis in pediatric leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 51:66-70. 2008
    ..Only isolated cases of PAP have been reported, and pediatric experience is limited...
  13. ncbi request reprint Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1
    Hiroto Inaba
    Department of Pediatrics, Mie University School of Medicine, Tsu, Mie 514 8507, Japan
    Int J Oncol 27:573-9. 2005
    ..Screening for similar Fas mutations in therapy resistant malignancies would lead to a better understanding of tumorigenesis and recurrence...
  14. pmc BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    J Pediatr 151:215-7. 2007
    ..Careful administration of chemotherapy and anti-viral therapy prevented further damage. This diagnosis should be considered in children who experience renal dysfunction during cancer treatment...
  15. ncbi request reprint Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8
    Hiroto Inaba
    Division of Pediatric Hematology Oncology, Children s Hospital of Michigan, Detroit, Michigan, USA
    Pediatr Blood Cancer 43:729-36. 2004
    ..Because the Fas ligand/Fas receptor (CD95, APO-1) apoptosis pathway is a potential therapeutic target in osteosarcomas, we examined the effect of IFN-gamma on Fas-induced apoptosis in four osteosarcoma cell lines...
  16. ncbi request reprint A case of hemoglobin SC disease with cold agglutinin-induced hemolysis
    Hiroto Inaba
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Am J Hematol 78:37-40. 2005
    ..Careful evaluation of CBCs and peripheral blood smears is required in cases of worsening anemia among sickle cell patients and consideration should be given to cold hemagglutinin disease as an etiology...
  17. pmc Treatment outcome in older patients with childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 118:6253-9. 2012
    ..To the authors' knowledge, the impact of age relative to that of other prognostic factors on the outcome of patients treated in recent trials is unknown...
  18. pmc Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia
    Sima Jeha
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee
    Cancer 120:1514-9. 2014
    ..To date, no data are available on the impact of TKIs on minimal residual disease (MRD) at the end of induction therapy among patients who have a poor early response to 2 weeks of induction therapy that does not include TKIs...
  19. pmc Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation
    Hiroto Inaba
    Department of Bone Marrow Transplantation and Cellular Therapy, MS 1130, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 3678, USA
    J Clin Oncol 30:3991-7. 2012
    ..To measure longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation (HSCT)...
  20. pmc Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia
    Shuiying Hu
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    J Natl Cancer Inst 103:893-905. 2011
    ..We investigated a treatment strategy combining sorafenib, a multikinase inhibitor with limited single-agent activity in AML, and cytarabine, a key component of AML chemotherapy...
  21. pmc Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital and the University of Tennessee Health Science Center, Memphis, TN 38105 2794, USA
    Lancet Oncol 11:543-52. 2010
    ....
  22. ncbi request reprint Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia
    Carol O'Hear
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
    Cancer 119:4036-43. 2013
    ..However, to the best of the authors' knowledge, the effects of GO on levels of minimal residual disease (MRD) are unknown...
  23. pmc Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
    Eric I Zimmerman
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN
    Blood 122:3607-15. 2013
    ..These preclinical data demonstrate that crenolanib is effective against FLT3-ITD containing secondary KD mutations, suggesting that crenolanib may be a useful therapeutic agent for TKI-naive and drug-resistant FLT3-ITD-positive AML. ..
  24. pmc Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia
    Sharyn D Baker
    Authors Affiliations Departments of Pharmaceutical Sciences, Structural Biology, Pathology, and Oncology, Hartwell Center for Bioinformatics and Biotechnology, St Jude Children s Research Hospital and Department of Pediatrics, University of Tennessee, Memphis, Tennessee
    Clin Cancer Res 19:5758-68. 2013
    ....
  25. pmc Improved prognosis for older adolescents with acute lymphoblastic leukemia
    Ching Hon Pui
    St Jude Children s Research Hospital, Memphis, TN 38105, USA
    J Clin Oncol 29:386-91. 2011
    ..We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group...
  26. pmc Ontogeny and sorafenib metabolism
    Eric I Zimmerman
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Clin Cancer Res 18:5788-95. 2012
    ..To investigate the role of ontogeny in sorafenib metabolism to the equipotent active metabolite sorafenib N-oxide...
  27. pmc Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia
    Jassada Buaboonnam
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 3678, USA
    Pediatr Blood Cancer 60:1161-4. 2013
    ..The efficacy of combination chemotherapy with methotrexate (MTX) and asparaginase is not well known in relapsed and refractory acute leukemia after contemporary therapy...
  28. pmc Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
    Cancer 120:1985-92. 2014
    ..Intensive chemotherapy for pediatric acute myeloid leukemia incurs the risk of infectious complications, but the benefits of antibiotic prophylaxis remain unclear...
  29. pmc Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
    Wing Leung
    Department of Bone Marrow Transplantation and Cellular Therapy, St Jude Children s Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105 2794, USA
    Blood 120:468-72. 2012
    ..Although MRD before HCT is a strong prognostic factor, its impact has diminished and should not be regarded as a contraindication for HCT...
  30. pmc Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation
    Hiroto Inaba
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 3678, USA
    Br J Haematol 156:109-17. 2012
    ..Patients at risk for vaccine failure should have long-term follow-up; those with loss of antibody response or no seroconversion should receive booster immunizations...
  31. ncbi request reprint Diagnostic challenge in recurrent skin rash after autologous bone marrow transplantation
    Hiroto Inaba
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Pediatr Hematol Oncol 28:525-8. 2006
    ..Establishment of diagnostic criteria and understanding of the pathophysiology of these entities may lead to better management and to improved therapy of refractory cancer...
  32. pmc NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105 2794, USA
    J Clin Oncol 28:955-9. 2010
    ..We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML...
  33. ncbi request reprint Definition of cure in childhood acute myeloid leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
    Cancer 120:2490-6. 2014
    ..The authors determined the likelihood that patients with AML would maintain long-term remission after the completion of therapy...
  34. pmc Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Cancer 119:2061-6. 2013
    ..However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown...
  35. pmc Alternative formulations of sorafenib for use in children
    Fariba Navid
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Pediatr Blood Cancer 60:1642-6. 2013
    ..We studied the chemical and physical stability of extemporaneously prepared formulations and evaluated the pharmacokinetic profile of cut tablets and smaller-dosage capsules of sorafenib in children...
  36. pmc Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia
    Karen D Wright
    Department of Oncology, St Jude Children s Research Hospital, University of Tennessee College of Medicine, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 60:E38-41. 2013
    ..Cases of DCL among pediatric patients have been reported to respond to therapeutic regimens for acute lymphoblastic leukemia, but details regarding the specifics of therapy are lacking...
  37. pmc Spinal epidural lipomatosis in children with hematologic malignancies
    Rachel C Brennan
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Ann Hematol 90:1067-74. 2011
    ..Investigation for SEL in leukemia or lymphoma patients with difficult lumbar punctures is warranted. Placement of an Ommaya reservoir may facilitate safe CNS-directed therapy in severely affected patients...
  38. pmc In vivo suppression of naive CD4 T cell responses by IL-2- and antigen-stimulated T lymphocytes in the absence of APC competition
    Hiroto Inaba
    Department of Oncology and Pathology, St Jude Children s Research Hospital, Memphis, TN, USA
    J Immunol 181:3323-35. 2008
    ..They further suggest a novel negative feedback loop limiting the expansion of T cell responses that may be present during vigorous immune responses or after IL-2 immunotherapy...
  39. pmc Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51
    Chengzhi Xie
    Department of Oncology, Wayne State University School of Medicine, Detroit, Michigan, United States of America Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States of America The State Engineering Laboratory of AIDS Vaccine, College of Life Science, Jilin University, Changchun, China
    PLoS ONE 8:e79106. 2013
    ....
  40. ncbi request reprint Allogeneic graft-versus-hepatoblastoma effect
    Hiroto Inaba
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pediatr Blood Cancer 46:501-5. 2006
    ..Her disease recurred when GVHD resolved. This patient's clinical course provides evidence for the probable existence of allogeneic graft-versus-hepatoblastoma effect...
  41. pmc Parainfluenza virus infections in children with hematologic malignancies
    Ashok Srinivasan
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Pediatr Infect Dis J 30:855-9. 2011
    ..However, the epidemiology of PIV infections in children with cancer has not been well studied...
  42. pmc Pulmonary function after whole lung irradiation in pediatric patients with solid malignancies
    Megan S Motosue
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Cancer 118:1450-6. 2012
    ..Although whole lung irradiation is used to treat pulmonary metastases of pediatric solid malignancies, few studies have addressed its long-term pulmonary consequences...
  43. ncbi request reprint Defective cell cycle induction by IL-2 in naive T-cells antigen stimulated in the presence of refractory T-lymphocytes
    Hiroto Inaba
    Department of Hematology and Oncology, St Jude Children s Research Hospital, 332 North Lauderdale Street, Memphis, TN 38105, USA
    Int Immunol 18:1043-54. 2006
    ..These results have implications for how activation-refractory T cells may influence nascent immune responses...
  44. pmc Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings
    Fulvia Brugnoletti
    Department of Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Pediatr Blood Cancer 52:293-5. 2009
    ..Resolution of diffusion abnormalities did not preclude further toxicity and a large lesion could cause persisting symptoms...
  45. pmc Childhood acute myeloid leukaemia
    Jeffrey E Rubnitz
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Br J Haematol 159:259-76. 2012
    ....